This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03488693
Recruitment Status : Recruiting
First Posted : April 5, 2018
Last Update Posted : April 12, 2024
Sponsor:
Collaborators:
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
NRG Oncology
SWOG Cancer Research Network
Information provided by (Responsible Party):
Canadian Cancer Trials Group

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Condition or disease Intervention/treatment Phase
Breast Cancer Radiation: Radiation Other: No Radiation Phase 3

Detailed Description:
Women with node positive breast cancer normally will receive endocrine therapy and some may receive chemotherapy to help prevent the cancer from coming back. Many women will also receive radiotherapy to the whole breast/chest area and the surrounding lymph glands (called regional radiotherapy). No one really knows whether patients with low risk breast cancer need to receive regional radiotherapy. Some women may be getting regional radiotherapy who do not need it. These women may be exposed to the side effects of their treatment without benefit.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Actual Study Start Date : October 16, 2018
Estimated Primary Completion Date : September 1, 2027
Estimated Study Completion Date : December 30, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: No Regional Radiotherapy
A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
 Radiation: Radiation
Radiotherapy given

Other: No Radiation
No radiotherapy given
Active Comparator: Regional Radiotherapy
A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
 Radiation: Radiation
Radiotherapy given


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC.


Secondary Outcome Measures :
  1. Compare the invasive disease-free survival between patients that received regional RT or not. [ Time Frame: 9.5 years ]
    Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast, regional nodes, distant sites or death due to BC

  2. Compare the breast cancer mortality between patients that received regional RT or not. [ Time Frame: 9.5 years ]
    Defined as death due to BC

  3. Compare the overall survival (OS) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    Defined as the time from randomization to the time of death from any cause

  4. Compare the locoregional recurrence-free interval (LRRFI) between patients that received regional RT or not. [ Time Frame: 9.5 years ]
    Defined as time from randomization to time of invasive recurrent disease in the ipsilateral chestwall, breast or regional nodes, or death to due to BC

  5. Compare the distant recurrence-free interval (DRFI) between patients that received regional RT or not. [ Time Frame: 9.5 years ]
    Defined as time from randomization to time of invasive recurrent disease in distant sites or death due to BC

  6. Number and severity of adverse events using the current CTCAE version 4 [ Time Frame: 9.5 years ]
  7. Compare arm volume and mobility measurements between patients that received regional RT or not [ Time Frame: 9.5 years ]
    A Fisher's Exact Test will be used to compare lymphedema and arm abduction deficit between two arms. Defined as a difference in arm abduction of 10% or greater in the comparison of the ipsilateral to the contralateral arm.

  8. Compare patient-reported outcomes (PROs) and the quality of life (QOL) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    using the NSABP Questionnaire for patients treated by BCS or mastectomy.

  9. Compare the quality of life (QOL) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    Overall QOL (EORTC QLQ-C30) will be compared between the two treatment groups using a similar approach.

  10. Compare the cost-effectiveness between patients that received regional RT or not [ Time Frame: 9.5 years ]
    Costs will be expressed in $US and $CAN base currencies based on the final year of the study. An average cost per study subject by treatment arm for an overall mean cost per study arm will be generated

  11. Compare the quality of life (QOL) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    breast symptoms (NSABP B32 Questionnaire) will be compared between the two treatment groups using a similar approach.

  12. Compare the quality of life (QOL) between patients that received regional RT or not [ Time Frame: 9.5 years ]
    skin symptoms and fatigue (EORTC QLQ-BR23) will be compared between the two treatment groups using a similar approach.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be women with newly diagnosed histologically proven invasive carcinoma of the breast with no evidence of metastases, staged as per site standard of care.
  • Patients must have been treated by BCS or mastectomy with clear margins of excision. Post-mastectomy positive margins for invasive disease and/or DCIS is not allowed. Multifocal disease (i.e. the presence of two or more foci or breast cancer within the same breast quadrant) and multicentric disease (i.e. the presence of two or more foci of breast cancer in different quadrants of the same breast) are allowed.
  • Patients with T3N0 disease are eligible.
  • Patients with disease limited to nodal micrometastases are eligible
  • Patients with nodal macrometastases (>2mm) treated by axillary dissection must have 1-3 positive axillary nodes (macrometastases, > 2 mm).
  • Patients treated by mastectomy and SLNB alone must have only 1-2 positive axillary nodes (macrometastases, > 2 mm).
  • Patients must be ER ≥ 1% and HER2 negative on local testing
  • Patients must have an Oncotype DX recurrence score ≤25 obtained from testing of breast tumour tissue from a core biopsy or from the surgical specimen.
  • Patient must consent to provision of, and investigator(s) must agree to submit to the CCTG Central Tumour Bank, a representative formalin fixed paraffin block of tumour tissue in order that the specific correlative marker assays described in the protocol may be conducted
  • Patient must consent to provision of samples of blood in order that the specific correlative marker assays described in the protocol may be conducted.
  • Patients must have had endocrine therapy initiated or planned for ≥ 5 years. Premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered. For all patients, endocrine therapy can be given concurrently or following RT.
  • Patients may or may not have had adjuvant chemotherapy.
  • RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy. If adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose. (Note: adjuvant chemotherapy may be ongoing at the time of randomization). Definitive surgery is defined as the last breast cancer-related surgery.
  • Patient's ECOG performance status must be 0, 1 or 2.
  • Patient's age must be ≥ 35 years.
  • For the first 736 eligible English or French-speaking subjects who have agreed to optional questionnaire completion: Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life, health utilities and lost productivity questionnaires in either English or French (note: enrollment completed 2022Aug02)
  • Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
  • Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
  • In accordance with CCTG policy, protocol treatment is to begin within 6 weeks of patient randomization.
  • Women of childbearing potential must have agreed to use an effective contraceptive method. A woman is considered to be of "childbearing potential" if she has had menses at any time in the preceding 12 consecutive months.

Exclusion Criteria:

  • Patients with nodal disease limited to isolated tumour cells (pN0i+ < 0.2 mm).
  • Patients with pT3N1 and pT4 disease (Note: patients with T3N0 are eligible).
  • Any prior history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated with radiation therapy. (Patients with synchronous or previous ipsilateral LCIS are eligible.)
  • Synchronous or previous contralateral invasive breast cancer. (Patients with contralateral DCIS are eligible unless previously treated with radiation.)
  • History of non-breast malignancies except adequately treated non-melanoma skin cancers, in situ cancers treated by local excision or other cancers curatively treated with no evidence of disease for ≥ 5 years.
  • Patients who are pregnant.
  • Patients that have had prior ipsilateral chestwall/thoracic radiation.
  • Patients treated with chemo or endocrine therapy administered in the neoadjuvant setting for breast cancer. Endocrine therapy exposure 12 weeks or less prior to surgery is permitted.
  • Patients with serious non-malignant disease (e.g. cardiovascular, scleroderma etc.) which would preclude RT.
  • Patients with any serious active or co-morbid medical conditions, laboratory abnormality, psychiatric illness, active or uncontrolled infections, or serious illnesses or medical conditions that would prevent the patient from participating or to be managed according to the protocol (according to investigator's decision).
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03488693


Contacts
Layout table for location contacts
Contact: Wendy Parulekar 613-533-6430 wparulekar@ctg.queensu.ca

Locations
Show Show 433 study locations
Sponsors and Collaborators
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology
Eastern Cooperative Oncology Group
NRG Oncology
SWOG Cancer Research Network
Investigators
Layout table for investigator information
Study Chair: Timothy Whelan Juravinski Cancer Centre at Hamilton Health Sciences, Ontario Canada
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Canadian Cancer Trials Group
ClinicalTrials.gov Identifier: NCT03488693    
Other Study ID Numbers: CCTG MA.39
NCI-2017-02047 ( Other Identifier: NCI CTRP )
First Posted: April 5, 2018    Key Record Dates
Last Update Posted: April 12, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases